On October 3, 2025 Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, reported it will present new data from the company’s in vivo HSC engineering platform in two poster sessions at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 40th Annual Meeting, hosted November 5-9 in National Harbor, Md (Press release, Ensoma, OCT 3, 2025, View Source [SID1234656432]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentations at SITC (Free SITC Whitepaper) 40th Annual Meeting:

Title: Discovery of lineage specific regulatory elements for development of in vivo CAR immune cell therapy via hematopoietic stem cell engineering
Abstract Number: 1019
Poster Presentation Time/Date: Friday, November 7, 5:10-6:35 pm EST
Location: Gaylord National Resort and Convention Center – Lower Level Atrium – Prince George’s ABC
Presenter: Alvin Pratama, Ph.D., Ensoma
Title: In vivo HSC engineering with VLPs generates lineage-restricted, multiplexed CAR-M, NK, and T cells to cooperatively mediate robust and durable solid tumor control in pre-clinical models
Abstract Number: 302
Poster Presentation Time/Date: Saturday, November 8, 5:10-6:35 pm EST
Location: Gaylord National Resort and Convention Center – Lower Level Atrium – Prince George’s ABC
Presenter: Yiwen Zhao, Ph.D., Ensoma